Category: News This Week

  • BAT and Accenture Partner

    BAT and Accenture Partner

    BAT and Accenture have entered into a global strategic partnership.

    As part of the strategic partnership, BAT will transform its Global Business Solutions function and Supply Network Operations. This collaboration will help simplify processes, improve speed to market, enhance compliance agility and create a foundation for future growth.

    The agreement will also provide BAT with access to Accenture’s comprehensive technological capabilities—including analytics and Agentic AI solutions—as well as its global learning capabilities.

    “At BAT, we are building a future-ready operating model—one that puts talent, technology, and trusted partnerships at its core,” said Tadeu Marroco, BAT CEO. “This agreement is more than operational change—it is a step toward a new way of working: one which is interconnected, agile, and underpinned by a digital ecosystem.

    “This approach reflects a broader commitment to how BAT is evolving its business model, developing strategic partnerships with industry leaders with world-class expertise.”

    “BAT has a bold vision to evolve its business to a dynamic new operating model, and we are excited to serve as its reinvention partner,” said Julie Sweet, Accenture chair and CEO. “Through our collaboration, we will harness the power of technology, data, AI, and our robust ecosystem of platform partners and share our deep expertise to help BAT modernize its operations and strengthen its agility and resilience.

    “This new way of working, fueled by connected, strategic partnerships, will help BAT raise the bar for innovation, create value, and drive sustainable growth.”

  • FDA Seeks Nominations for the Tobacco Products Scientific Advisory Committee

    FDA Seeks Nominations for the Tobacco Products Scientific Advisory Committee

    The U.S. Food and Drug Administration is requesting nominations by Aug. 25, 2025, for voting members to serve on the Tobacco Products Scientific Advisory Committee (TPSAC). Individuals may self-nominate or be nominated by any interested person or organization.

    Specifically, TPSAC is seeking to fill five vacancies with physicians, dentists, scientists, or healthcare professionals practicing in oncology, pulmonology, cardiology, toxicology, pharmacology, addiction, engineering, or any other relevant specialty. Included in the five vacancies is one vacancy for a representative of the general public and one vacancy for an employee of federal, state, or local government. Selected members will be invited to serve for terms of up to four years, which will begin on Feb. 1, 2026, after the current members’ terms expire.

    All nominations for membership should be sent electronically to the FDA Advisory Nomination Portal or by mail to Advisory Committee Oversight and Management Staff. Please see the Federal Register notice for further information. Nominations received after Aug. 25, 2025, will be considered for nomination to the committee as later vacancies occur.

    TPSAC advises the FDA in its responsibilities related to the regulation of tobacco products, such as any application submitted by a manufacturer for a modified-risk tobacco product. The committee reviews and evaluates safety, dependence, and health issues concerning tobacco products and provides appropriate advice, information, and recommendations to the FDA commissioner.

  • Tobacco Use Among Indian Women Declines

    Tobacco Use Among Indian Women Declines

    Recent public health data from India reveal a decline in female tobacco use, from 20.3% to 14.2%, attributed to intensified anti-tobacco educational campaigns and regulatory action. Despite the decline, secondary exposure remains a critical issue: over 64% of secondhand smoke–related fatalities involve women. Health officials stress that many tobacco-related illnesses emerge much later, even after use declines, so earlier prevalence continues to contribute to disease burden.

  • Taiwan: HTPs Given Conditional Approval, Blocked For Personal Import

    Taiwan: HTPs Given Conditional Approval, Blocked For Personal Import

    Taiwan’s Health Promotion Administration has conditionally approved 14 heated tobacco products for legal sale under the revised Tobacco Hazards Prevention Act, the agency announced Tuesday. Customs confirms that personal imports of heated tobacco products (HTPs) remain prohibited.

    Lo Shu-ying, head of the HPA’s Tobacco Control Division, said the approval process will follow the same procedures used for traditional tobacco products, including a review of packaging and product contents.

    Lo added that the HPA will work with the Customs Administration and the Ministry of Finance to discuss supporting measures, such as the import of heated tobacco products by individuals and the collection of tobacco surcharges, but only after the current administrative reviews are completed.

  • New Zealand: PMI Tax Incentive Extended Through 2027

    New Zealand: PMI Tax Incentive Extended Through 2027

    New Zealand’s tax incentive for Heated Tobacco Products, initially introduced in mid-2024 as a one-year pilot, has been extended for two additional years, with the formal review now moved to July 2027. The excise tax was halved in a bid to encourage smokers to switch from combustible cigarettes to less harmful alternatives.

    The initial trial failed to generate viable data: health ministry briefings confirmed that Philip Morris did not pass cost savings to consumers in the critical early phase, and IQOS devices were removed from shelves for approximately five months due to non‑compliance with battery-removability regulations. Officials described any evaluation at that point as “meaningless,” given that reduced priced HTPs were unavailable for the majority of the trial period.

    Associate Health Minister Casey Costello justified the extension by citing her own “independent advice,” later revealed to consist of five articles—many outdated or about different products—that offered only marginal support for HTP-friendly tax policy. Treasury officials warned that Philip Morris, as the sole importer, would reap the bulk of the estimated NZ$200–300 million cost over the extended term.

    Opposition health advocates suggest the extension favors multinational manufacturers—particularly Philip Morris, which dominates New Zealand’s HTP market—and question whether it undermines broader tobacco control efforts. Government officials maintain that lifting the removable battery requirement for IQOS was a necessary compliance fix and that further data is essential to assess whether price reductions have prompted meaningful user transitions away from conventional cigarettes.

    Cabinet and Costello’s office emphasized the need for more robust market data before concluding the HTP pilot. The extended evaluation, now slated for 2027, will not only assess smoker uptake but also unintended demographic use—particularly young people—and any substitution away from vaping or cigarettes. Simultaneously, documents released from JUUL litigation revealed lobbying initiatives targeting NZ First, alleging PMI had pitched draft regulations to align with its interests. While party leaders deny wrongdoing, critics highlight the decision as symptomatic of “highly industry-friendly” policymaking.

  • Minnesota Mandates “Mental Health Warning” Labels on Social Platforms

    Minnesota Mandates “Mental Health Warning” Labels on Social Platforms

    Minnesota lawmakers have enacted what’s believed to be the nation’s first statutory requirement for social media platforms to display a conspicuous mental health warning at every login. Under HF 1289, effective July 1, 2026, platforms must show a pop-up label warning of risks such as anxiety, depression, addiction and cyberbullying, and must include crisis hotline information like the 988 Lifeline. The label stays onscreen until the user either acknowledges it or exits the app; it may not be bypassed or hidden within fine print. Health commissioners must issue implementation guidelines by March 1, 2026.

    Supporters argue the policy fills a regulatory gap in public health communications, drawing parallels to tobacco warning labels. Critics warn it may raise free-speech concerns and pose enforcement challenges, especially given the global footprint of leading social media platforms.

  • Philip Morris International Reports Record Q2 Earnings

    Philip Morris International Reports Record Q2 Earnings

    Philip Morris International Inc. reported record second-quarter results today (July 22) driven by strong growth in its smoke-free portfolio and resilient performance in combustibles. Net revenues reached an all-time high, with smoke-free products—including IQOS, ZYN, and VEEV—accounting for 41% of total sales. Shipments of smoke-free products rose 11.8%, while gross profit from the category jumped over 23%.

    CEO Jacek Olczak highlighted a “reacceleration” in IQOS and ZYN sales, especially in Europe, Japan, and the U.S., where ZYN’s offtake rose 36% in June. PMI’s e-vapor brand VEEV more than doubled shipment volumes, now leading in several European markets.

    Combustible products like Marlboro remained stable, contributing to a 2.1% revenue increase despite expected volume declines. PMI also declared a quarterly dividend of $1.35 per share. Buoyed by strong year-to-date performance, the company raised its full-year earnings guidance.

    Click here for the full financial report.

  • Cresco Labs to Exit California Cannabis Market

    Cresco Labs to Exit California Cannabis Market

    Cresco Labs Inc. announced plans to sell its California operations as part of a strategic restructuring aimed at boosting cash flow and focusing on higher-margin markets. The multistate cannabis operator is in talks with buyers for its cultivation, manufacturing, and select distribution assets in California, with a deal expected in the coming quarters. Cresco will retain its premium FloraCal brand, continuing its presence in key U.S. markets.

    CEO Charlie Bachtell cited California’s “structural challenges” and the lack of a scaled footprint as reasons for the exit, saying the move will allow Cresco to reallocate capital to core and emerging markets with clearer growth potential.

  • Study: 78M Cigarettes Smoked Daily in Britain

    Study: 78M Cigarettes Smoked Daily in Britain

    More than 78 million cigarettes are smoked each day across England, Wales, and Scotland—equating to roughly 900 every second—according to a new study by University College London (UCL), funded by Cancer Research UK.

    The study, published in Nicotine & Tobacco Research, highlights sharp inequalities in smoking habits. People from lower socioeconomic backgrounds smoke more—11 cigarettes a day on average—compared to 9.4 among more affluent groups. Regionally, smokers in the North East and Scotland top the charts with 11.7 cigarettes per day, while Londoners smoke the fewest at 8.4.

    Despite falling smoking rates—from 18.8% in 2013 to 11.9% in 2023—Britain is unlikely to meet its smokefree targets. England, aiming for 5% prevalence by 2030, is projected to hit that mark by 2039. Scotland may not reach it until the late 2040s.